Sab Biotherapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
SAB Biotherapeutics, Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 18, 2026.
NASDAQ
SAB Biotherapeutics calls a special meeting to approve the conversion of Series B Preferred Stock and an expanded equity plan, potentially leading to over 2,500% common stock dilution.
NASDAQ
SAB Biotherapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on July 17, 2025, where shareholders will vote on the election of four Class I directors and the ratification of EisnerAmper LLP as the independent registered public accounting firm, following a prior auditor's 'going concern' note and financial restatement.
NASDAQ
SAB Biotherapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 27, 2024, to vote on key proposals including the election of directors and an amendment to the company's equity incentive plan.